Chronic repeated gavage dosing of high concentrations of ethyl acrylate (EA) causes forestomach tumors in rats and mice. For two decades, there has been general consensus that these tumors are unique to rodents because of: i) lack of carcinogenicity in other organs, ii) specificity to the forestomach (an organ unique to rodents which humans do not possess), iii) lack of carcinogenicity by other routes of exposure, and iv) obvious site of contact toxicity at carcinogenic doses. In 1986, EA was classified as possibly carcinogenic to humans by the International Agency for Research on Cancer (IARC). However, by applying a MOA analyses and human relevance framework assessment, the weight-of-evidence supports a cytotoxic MOA with the following key events: i) bolus delivery of EA to forestomach lumen and subsequent absorption, ii) cytotoxicity likely due to saturation of enzymatic detoxification, iii) chronic regenerative hyperplasia, and iv) spontaneous mutation due to increased cell replication and cell population. Clonal expansion of initiated cells thus results in late onset tumorigenesis. The key events in this 'wound and healing' MOA provide high confidence in the MOA as assessed by evolved Bradford-Hill Criteria. The weight-of-evidence supported by the proposed MOA, combined with a unique tissue that does not exist in humans, indicates that EA is highly unlikely to pose a human cancer hazard.
Introduction
Ethyl acrylate (EA) is an acrylic monomer used in the production of polymers and copolymers in plastics, latex paints, textiles, paper products, and other items (NTP, 1986; SCOEL, 2004) . It is a major monomer in styrene-based polymers and can be found in polymers used for medical devices and dental items (IARC, 1986) . It is also found naturally in fruits (IARC, 1986) . Although not used significantly as a flavoring agent today (Health Canada, 2011) , the U.S. Food and Drug Administration considers EA as generally regarded as safe (GRAS) as a flavoring agent in foods and beverages (U.S. FDA, 1983) . Williams and Iatropoulos (2009) state that annual production in 2005 in the US and Europe was 250,000-500,000 tons and 50-100,000 tons, respectively. According to U.S. EPA sources, available national aggregate production volume data from the most recent year (2015) was 250M-500M pounds (113,000-226,000 million metric tons) (U.S. EPA, 2015) .
EA induced forestomach tumors in rodents following repeated oral gavage exposure at high doses that induced chronic tissue damage (Ghanayem et al., 1993; NTP, 1986) . EA is perhaps one of the few rodent carcinogens recognized by many scientists and organizations as unlikely to be carcinogenic to humans. For example, the National Toxicology Program (NTP) listed EA as "reasonably anticipated to be carcinogenic to humans" in 1989, but subsequently delisted the compound citing evidence for low human exposure, specificity of effect by oral gavage, and evidence for local irritation and cell proliferation in the forestomach (NTP, 2000; NTP, 2004) . Chronic injury to the forestomach epithelial lining resulting in tissue cytotoxicity and cell death results in an increased cell population and proliferation, which increases the probability of fixation of a spontaneous mutation. In a screening assessment conducted by Health Canada (2011), it was concluded that the likely mode of action (MOA) for EA-induced rodentspecific forestomach tumors involves a threshold which requires promotion via sustained irritation and hyperplasia. Stated differently, doses of EA that do not cause chronic cytotoxicity are unlikely to be carcinogenic to rodents. Based on margin of exposure analysis, questionable relevance of forestomach tumors to humans, and lack of bioaccumulation, Health Canada concluded that EA is unlikely to present a danger to human health (Health Canada, 2011) .
Classification of EA has evolved over time as data have become available on forestomach tumors. In 1986, the International Agency for Research on Cancer (IARC) classified EA as Group 2B, "possibly carcinogenic to humans" (IARC, 1986) , and it has retained that classification to date. EA was listed in 1989 as a chemical "known to the State of California" to cause cancer under the Safe Drinking Water and Toxic Enforcement Act of 1986 (commonly referred to as Proposition 65) (OEHHA, https://oehha.ca.gov/proposition-65/chemicals/ethylacrylate). The U.S. Environmental Protection Agency (EPA) developed a draft oral cancer slope factor for EA in 1987 (U.S. EPA, 2000) ; however, no cancer values for EA are currently listed in EPA' s Integrated Risk Information System (IRIS) database or regional screening level tables (U.S. EPA, 2017) . Although data relevant to the MOA for EA-induced forestomach tumors have been reviewed (OECD, 2004; Williams and Iatropoulos, 2009) , the data were not formally presented in the context of MOA and human relevance frameworks used by many regulators. Similarly, Health Canada (2011) concluded that the MOA for forestomach tumors supported a threshold point of departure for regulatory management but did not formally present a MOA analysis. The purpose of this article is to review data related to EA-induced forestomach tumors within accepted MOA and human relevance frameworks. It is anticipated that such MOA and human relevance assessments will be informative for future regulatory decisions and activities related to EA.
Overview of ethyl acrylate carcinogenicity
The chronic oral toxicity of EA was first reported in 1964; however, no carcinogenicity was reported, including the gastrointestinal tract, nor were any histopathological lesions considered to be treatment related (Borzelleca et al., 1964) . The dogs and rats in this study were respectively exposed to up to 1000 and 2000 ppm EA in capsules and drinking water daily for two years. Citing high production volume for EA and worker exposure (primarily via inhalation and dermal exposure) as a basis for evaluation, the National Toxicology Program (NTP) conducted 2-week, 13-week, and 2-year oral gavage studies in F344 rats and B6C3F 1 mice with EA in corn oil (NTP, 1986) . In the 2-week studies, a few rodents exposed to 100 and 200 mg/kg EA exhibited thickening of the forestomach, whereas the majority of rodents exposed to ≥400 mg/kg exhibited mucosal thickening. In the 13-week studies, rodents were exposed to lower doses (7-110 mg/kg), and no histopathological lesions were observed. Due to the severity of lesions at 400 mg/kg in the 2-week studies, 200 mg/kg was selected as the highest dose for the 2-year bioassay.
The NTP 2-year studies included only three groups (0, 100, 200 mg/ kg). Carcinogenicity was limited to the forestomach of both sexes of rats and mice (Table 1) . Non-neoplastic lesions in the forestomach of both treated groups included hyperkeratosis, epithelial hyperplasia, and inflammation. Hyperkeratosis is often observed together with hyperplasia (Greaves, 2007; Kooistra and Nyska, 2014) , and the incidences were similar for hyperkeratosis and hyperplasia in the NTP study (Table 1) . Inflammation was present at a lower incidence than hyperplasia and hyperkeratosis. Squamous cell papillomas were more prevalent than carcinomas at both doses among both species and sexes (Table 1) . A subsequent carcinogenicity study examined the role of cell proliferation in EA-induced forestomach cancer. Specifically, F344 rats were Table 1 Summary of forestomach lesions in 2-year cancer bioassay.
Rats Males Females
Ethyl acrylate (mg/kg-day)  0  100  200  0  100  200  n  5 0  5 0  5 0  5 0  5 0  5 0  hyperkeratosis  0  37  46  0  24  46  epithelial hyperplasia  1  41  46  0  34  49  acute or chronic inflammation  1  8  28  1  3  20  squamous cell papilloma  1  15  29  1  6  9  squamous cell carcinoma  0  5  12  0  0  2  papilloma or carcinoma  1  18  36  1  6 Adapted from (NTP, 1986) . Fig. 1 . Summary of oral gavage hyperplasia and carcinogenicity data for ethyl acrylate in long-term studies in male rats. ND, not done.
administered 200 mg/kg EA in corn oil for 6 or 12 months and then allowed to recover (Ghanayem et al., 1993) . As shown in Fig. 1 , no neoplasms were observed immediately following 6 or 12 months of exposure to 200 mg/kg EA; however, all treated rats exhibited mucosal hyperplasia. Rats exposed to EA for 6 months and then necropsied after 15 months without exposure (18 animals per group) exhibited neither hyperplasia nor tumors. In contrast, rats exposed to EA for 12 months and then necropsied after 9 months without exposure exhibited mucosal hyperplasia (8/13) and forestomach neoplasms (4/13). The mucosal hyperplasia observed in rats exposed for 12 months followed by 9 months of recovery could be due to insufficient time for complete resolution (i.e. 9 months vs 15 months in the other group). Alternatively, the hyperplasia could be the result of an increase in the overall cell population during the 12 months of exposure, thus making these tissues appear more hyperplastic months after exposure was terminated. As discussed in the section below, repeated exposure to EA can lead to tissue remodeling evidenced by folding of the mucosa.
The above rodent bioassays demonstrated that chronic repeated oral bolus gavage administration of ≥100 mg/kg-day EA caused neoplastic lesions in the forestomach of male and female mice and rats, but no other treatment-related tumors. By comparison, some estimates of human oral exposure are on the order of 0.01-0.03 μg/kg-day (WHO, 2006; Williams and Iatropoulos, 2009) .
The chronic toxicity and carcinogenicity of EA was also investigated in F344 rats and B6C3F 1 mice via inhalation exposure (Miller et al., 1985) . Rodents exposed to up to 75 ppm for 27 months did not develop treatment-related neoplasms. Exposure to 225 ppm EA was overtly toxic to rats and mice, and thus exposure was terminated after 6 months. Rodents that were exposed to 225 ppm EA for 6 months and that survived an additional 21 months did not exhibit treatment-related neoplasms (Miller et al., 1985) . The only notable histopathological lesions in these studies were nonneoplastic compensatory hyperplasia in the nasal cavity and olfactory epithelium. Dermal exposure studies in wild type and transgenic Tg.AC mice were negative for carcinogenicity (DePass et al., 1984; Nylander-French and French, 1998) .
We found no epidemiological studies that reported a reliable indication of carcinogenic risk from oral or inhalation exposure to EA. This is consistent with earlier evaluations of EA carcinogenicity (Health Canada, 2011; IARC, 1986; IARC, 1999; NTP, 2000; NTP, 2004; SCOEL, 2004) and the most recent review (Suh et al., 2018, in press ). Only one cancer epidemiology study of worker cohorts exposed to acrylate monomers, specifically EA and methyl methacrylate, was identified (Walker et al., 1991) . This study retrospectively evaluated colon and rectal cancer mortality of three occupational cohorts in two plants where acrylate monomers were manufactured and polymerized between 1933 and 1982. In a report on the earliest worker cohort, excess colon and rectal cancer were reported among males employed during the early 1940s. In contrast, no excess mortality was observed among the two later worker cohorts. The exposure characterizations were based on recollections by long-term employees, and no distinction was made between EA and methyl methacrylate exposures, or the presence of other chemicals in the workplace (e.g., lead, ethylene dichloride, acrylonitrile). Importantly, the study did not account for confounding factors such as smoking, alcohol use, and personal history of inflammatory bowel disease (ACS, 2017) . Overall, the available human data are inadequate to provide evidence of a causal relationship between EA exposure and elevated cancer risk.
Application of the mode of action framework
As noted in Proctor et al. (2007) , there is no generic MOA for forestomach cancer, as the toxicity profiles of forestomach carcinogens vary greatly. Some are genotoxic and others non-genotoxic, and some are organ specific and others induce cancer in multiple organs. As such, it is important to conduct a MOA analysis with the available data specific to EA. The U.S. EPA's Guidelines for Carcinogen Risk Assessment outlines a MOA framework for describing the key events underlying chemical-mediated carcinogenicity (U.S. EPA, 2005) . This MOA framework is similar to those proposed by the other scientists and organizations (Boobis et al., 2006 (Boobis et al., , 2008 Meek and Klaunig, 2010; SonichMullin et al., 2001) . U.S. EPA defines a key event as "an empirically observable and quantifiable precursor step that is itself a necessary element of the mode of action or is a biologically based marker for such an element." Key events are events that, if prevented, would likely block progression to adverse outcomes such as cancer. Ideally, MOA analysis should be performed for each tumor site of interest and rely heavily upon target tissue-specific data. As forestomach tumors are the only tumors related to oral exposure to EA, it is the sole focus of this MOA analysis. Because forestomach tumors are observed in both rats and mice, relevant data will be discussed from both species.
Summary of the key events in the MOA for forestomach tumors
Based on review of histological, biochemical, and pharmacokinetic data on EA, we conclude that the overall weight of evidence (WOE) supports a non-mutagenic, threshold MOA with the key events shown in Fig. 2 . Key Event 1 entails bolus delivery and uptake of ethyl acrylate from the forestomach lumen; Key Event 2 entails EA binding to cellular thiols and enzymatic conversion to acrylic acid and subsequent cellular toxicity; Key Event 3 involves sustained compensatory hyperplasia to repair/replace the damaged mucosa; and Key Event 4 is spontaneous mutation resulting from increased cell replication over the life of the animal. Under prolonged exposure scenarios, this can increase the risk of tumorigenesis in the rodent forestomach. Each of these key events, and supporting data, are summarized in the sections that follow.
3.1.1. Key Event 1: bolus delivery of EA to the forestomach Gastric intubation (i.e., gavage dosing) results in placement of test article directly into the forestomach lumen of the rodent. Several studies indicate that it is not the overall body burden (mg/kg) of EA that causes forestomach toxicity, but rather the dose delivered to the forestomach lumen. Three studies have compared the toxicity of EA administered by gavage and drinking water. Frederick et al. (1990) exposed male F344 rats for two weeks to 2-200 mg/kg ethyl acrylate via corn oil gavage and 23-369 mg/kg ethyl acrylate via drinking water. Ethyl acrylate via gavage showed no effects at 2 and 10 mg/kg, induced hyperplasia and hyperkeratosis at ≥20 mg/kg, produced inflammation and edema at 100 and 200 mg/kg, and ulceration at 200 mg/kg. Drinking water exposure resulted in much milder effects with no forestomach lesions at 20 mg/kg, minimal hyperplasia (without hyperkeratosis) at 99 mg/kg, mild to marked hyperplasia (with hyperkeratosis) at ≥197 mg/kg, and slight elevations in inflammation at ≥99 mg/kg (Frederick et al., 1990) .
Two unpublished 90-day GLP studies from the same laboratory also compared the toxicity of EA via gavage and drinking water. In the gavage study conducted in male rats, exposure to EA for 4 or 13 weeks induced diffuse forestomach hyperplasia at ≥20 mg/kg and C.M. Thompson et al. Regulatory Toxicology and Pharmacology 96 (2018) 178-189 hyperkeratosis at ≥100 mg/kg (Table 2 ) (Bernacki et al., 1987b) . Inflammation and edema were also observed at both time points primarily in the highest treatment group, 200 mg/kg. None of the aforementioned lesions were present in rats exposed to 200 mg/kg EA for 4 weeks and then allowed to recover for 9 weeks. In the drinking water study, male and female rats received doses equivalent of up to 249 mg/kg and 293 mg/kg, respectively (Bernacki et al., 1987a) . After 13 weeks of exposure, forestomach hyperplasia was not observed in male rats exposed to 17 mg/kg EA, but was evident at ≥70 mg/kg; similarly, no forestomach hyperplasia was observed in female rats exposed to 20 mg/kg EA, but was observed at ≥87 mg/kg (Table 3) (Bernacki et al., 1987a) . In addition to the 13-week time point, rats were also examined after 1, 2 and 4 weeks of exposure. After 1 week of exposure, only 1/10 rats exhibited forestomach hyperplasia at ∼20 mg/kg, and no rats exhibited forestomach hyperplasia at ∼20 mg/kg at 2 and 4 weeks of exposure. All higher doses (≥70 mg/ kg) induced forestomach hyperplasia in most or all of the rats examined at the 1-, 2-, and 4-week time points.
As discussed above, it is clear that at comparable gavage and drinking water doses, EA induces different levels of toxicity, and gavage (but not drinking water) exposures are carcinogenic in rats and mice (Borzelleca et al., 1964; Ghanayem et al., 1993; NTP, 1986) . It has also been shown that acute exposure to 200 mg/kg EA induces forestomach toxicity (edema) by gavage but not by s.c. injection (Ghanayem et al., 1985a) . Intraperitoneal injection of 200 mg/kg resulted in some toxicity, which Ghanayem et al. postulated was due to absorption of EA through the abdominal wall. Rodents exposed to high levels of EA via inhalation or dermal routes also develop nonneoplastic lesions at the site of contact but no evidence of tumors (Miller et al., 1985; NylanderFrench and French, 1998) .
3.1.2. Key Event 2: EA binding to cellular thiols and enzymatic conversion to acrylic acid and subsequent cellular toxicity 3.1.2.1. Ethyl acrylate metabolism (binding of EA to cellular thiols and enzymatic conversion to acrylic acid). Fig. 3 summarizes the metabolism of EA which is mediated by three main pathways: (1) non-enzymatic conjugation to glutathione and other low molecular weight thiols (LMWTs), (2) binding to proteins, and (3) enzymatic conversion to acrylic acid by carboxylesterases as with other small acrylic esters (Miller et al., 1981; Silver and Murphy, 1981) . Comparisons of acute toxicity between methyl acrylate, EA, butyl acrylate, and acrylic acid indicate methyl acrylate is more acutely potent than EA, and that butyl acrylate and acrylic acid are comparatively non-toxic (Ghanayem et al., 1985b) . These finding indicate that toxicity decreases as the ester carbon chain increases in length. To assess the role of the α, β-unsaturated double bond, the toxicity of EA and methyl acrylate were compared to their respective saturated forms ethyl propionate and methyl propionate. Furthermore, addition of a methyl group at the α carbon was tested for methyl methacrylate and ethyl methacrylate. None of these saturated forms produced acute toxicity at equivalent doses to EA and methyl acrylate (Ghanayem et al., 1985b) .
Studies suggest that the toxicity of small acrylates is related to the ester linkage (longer chains being less toxic) and the unsaturated double bond. Specifically, in vitro binding assays indicate that α,β-unsaturated acrylic esters like methyl acrylate and EA readily bind the sulfhydryl group of cysteine but bind with less affinity to the amine group of glycine (Friedman et al., 1965) . Because of the cysteine present in the tripeptide glutathione (GSH), these α,β-unsaturated acrylic esters also bind to GSH; however, methyl substitution at the α carbon (e.g. ethyl methacrylate) severely limits GSH binding (McCarthy et al., 1994) . Detailed studies of EA indicate non-enzymatic conjugation with GSH forms 3-(glutathione-S-yl)ethylpropionate in vitro (Potter and Tran, 1992) . Overall, several studies suggest a second-order rate constant of 20-30 M −1 min −1 (Hashimoto and Aldridge, 1970; McCarthy et al., 1994; Potter and Tran, 1992) . These and other data (see below) indicate the possibility of binding to protein sulfhydryls. Indeed, EA binding to protein in various tissues was demonstrated to have similar rate constants as for GSH-likely indicating preferential binding to cysteine thiols (Potter and Tran, 1992) . Unlike methyl acrylate and EA, acrylic acid-a primary metabolite of EA-does not readily bind nonprotein sulfhydryls (or low molecular weight thiols, LMWTs) (Miller et al., 1981) -possibly due to the hydroxyl group hindering nucleophilic attack of the β carbon of the double bond. Acrylate esters are also metabolized by carboxylesterases and inhibition of carboxylesterases potentiated the acute toxicity of methyl acrylate and EA. In homogenized rat tissue extracts, methyl acrylate, EA, and butyl acrylate are hydrolyzed rapidly with disappearance of parent compound roughly equaling the rate of acrylic acid formation-indicating conversion by carboxylesterases (Frederick et al., 1992; Miller et al., 1981) . Inhibition of carboxylesterases with triorthotolyl phosphate (TOTP) inhibits EA metabolism in rat tissue homogenates (Silver and Murphy, 1981) . In addition, inhalation studies indicate that pretreatment of rats with TOTP potentiates the lethality of EA and methacrylate (but not acrylic acid), as well as potentiates the loss of LMWTs in lung, liver, kidney, and blood following 4 h of exposure (Silver and Murphy, 1981) . Pretreatment with TOTP had relatively little effect on LMWTs depletion by acrylic acid. Although inhalation of 1000 ppm acrylic acid greatly reduced LMWT levels, both in vivo and in vitro data indicate that acrylic acid -mediated depletion of LMWTs occurs much less readily than with EA treatment, indicating that LMWT depletion with 1000 ppm acrylic acid may be the result of other downstream events (Miller et al., 1981; Silver and Murphy, 1981) .
deBethizy et al. (1987) conducted an in-depth analysis of the pharmacokinetics of both EA and its metabolite acrylic acid. Orally Table 2 Forestomach lesions in male rats (gavage) (Bernacki et al., 1987b) . a reco = 9-week recovery group.
Table 3
Forestomach lesions in rats (13 weeks; drinking water) (Bernacki et al., 1987b) . Thompson et al. Regulatory Toxicology and Pharmacology 96 (2018) 178-189 administered EA is rapidly eliminated with 60% and 75% eliminated within 8 and 24 h, respectively. Approximately 50-60% is eliminated as expired CO 2 , while a large fraction is found in the urine as cysteine conjugates, N-acetyl-S-(carboxyethyl)cysteine and N-acetyl-S-(carboxyethyl)cysteine ethyl ester. These urinary metabolites are likely products of the 3-(glutathione-S-yl)ethylpropionate formed from GSH binding to EA (Potter and Tran, 1992) . As the dose of EA increased from 2 to 200 mg/kg, the percentage of EA recovered in the urine decreased from 28% to 8%, likely due to depletion of thiols. Roughly 10%-15% of EA was recovered in tissues. deBethizy et al. (1987) also demonstrated dose-dependent decreases in LMWTs at both 1 h and 4 h post exposure. Ghanayem et al. (1987) reported similar results as deBethizy et al. (1987) ; where approximately 70% of 200 mg/kg EA was expired as CO 2 , and the same urinary metabolites were identified along with an additional metabolite identified as N-acetyl-S-(carboxyethyl)cysteine-Soxide, and one unidentified peak on the HPLC chromatogram. Notably, this peak was determined not to be an acrylic acid conjugate of either GSH or cysteine. Several studies have informed both the pharmacokinetics and MOA for EA by experimentally altering EA disposition. Silver and Murphy (1981) demonstrated that carboxylesterase inhibition with TOTP potentiated the lethality and depletion of LMWTs in rats following inhalation exposure to EA. deBethizy et al. (1987) showed that both EA and acrylic acid increased forestomach weight (due to edema) 1 h after gavage dosing, and that TOTP enhanced the effect in the former but not the latter. Treatment with EA significantly reduced LMWTs in the forestomach and stomach; unlike for organ weight, pretreatment with TOTP had no effect on LMWTs. According to deBethizy et al. (1987) , this suggests that carboxylase metabolism does not compete with sulfhydryl depletion. Stated differently, sulfhydryl binding may be the predominant (or faster) 'clearance' pathway, with carboxylase-mediated metabolism being a secondary or concurrent pathway. That carboxylase inhibition potentiates toxicity might relate to the third clearance pathway of protein thiol binding.
Several studies have demonstrated that exposure to ∼200 mg/kg EA significantly depletes LMWT in the forestomach, with maximal depletion occurring within ∼4 h, return to baseline within 12 h, and a dramatic increase in GSH levels within 24 h (deBethizy et al., 1987; Frederick et al., 1990; Gillette and Frederick, 1993; Udinsky and Frederick, 1994 ). An example from an unpublished GLP study is shown in Fig. 4 (Udinsky and Frederick, 1994) . This same general pattern has been demonstrated after two weeks of repeated exposure (Gillette and Frederick, 1993 )-indicating that each bolus dose of EA creates a cycle of GSH depletion and rebound. It is evident, however, that the rebound and increase in GSH levels are not enough to protect against toxicity at the next daily 200 mg/kg bolus dose.
To investigate the role of GSH in the MOA, Ghanayem et al. (1991a) conducted several experiments to examine the toxicity of EA by altering sulfhydryl levels. In single dosing studies, pretreatment with cysteine or cysteamine (both via i.p.), increased acute toxicity as measured by increased forestomach weight/edema. Pretreatment with subcutaneous injection of diethylmaleate (DEM, a GSH-depleting compound) protected against forestomach toxicity. In a 14-day repeated dose study, pretreatment with cysteamine again enhanced forestomach toxicity (mucosal hyperplasia). Repeated treatment with DEM and EA resulted in frank toxicity (bodyweight loss) that precluded further analysis (Ghanayem et al., 1991a) . These findings were surprising to the study authors, as they suggest that GSH-conjugated-EA is itself the toxic moiety, rather than acrylic acid, GSH depletion, or protein binding. However, with regard to the mitigation of toxicity by DEM, it seems plausible that DEM-induced GSH depletion could be followed by an increase in GSH similar to those demonstrated by EA treatment (Fig. 4) . Indeed, others have reported that DEM increases GSH in the forestomach but not liver (Hirose et al., 1989; Shibata et al., 1993) . Moreover, the effects of DEM on EA toxicity may be confounded by other effects attributed to DEM exposure such as inhibition of protein synthesis, induction of hypothermia, altered cytochrome P450 expression, and alteration of inducible nitric oxide synthase expression (Costa and Murphy, 1986; Hirose et al., 1989; Kang et al., 1999) .
Because acrylic acid is a major metabolite of EA metabolism, it is informative to examine the available data on acrylic acid to inform the likely MOA for EA. As reviewed in Hellwig et al. (1993) , 3-month gavage study on acrylic acid resulted in limited forestomach hyperplasia at substantially higher doses than those required for EA (1M and 1F out of 10/sex rats at 150 mg/kg, 3M and 1F rat(s) out of 10/sex at 375 mg/ kg). Chronic bioassays with acrylic acid were conducted in drinking water at concentrations up to ∼331 mg/kg for 12 months or up to ∼78 mg/kg-day for two years; no cancers were observed, and no forestomach lesions reported (Hellwig et al., 1993) . These findings indicate that acrylic acid is not carcinogenic, thus supporting the importance of carboxylesterase serving as a protective first line of defense as a "Modifying Factor" that supports a threshold dose required to overwhelm carboxylesterase-mediated detoxification of EA.
Taken together, the data indicate that the toxicity of acrylate esters C.M. Thompson et al. Regulatory Toxicology and Pharmacology 96 (2018) 178-189 is mediated by the unsaturated double bond and influenced by the length of the ester carbon chain length. Ethyl acrylate is rapidly cleared, found bound to sulfhydryls, and causes dose-dependent depletion of GSH. This later component is consistent with a threshold whereby repeated thiol depletion may promote cytotoxicity as well as leave the cell vulnerable to other cytotoxic events such as oxidative stress.
3.1.2.2. Cellular toxicity. The toxicity of EA appears to be mediated within the cell rather than at the cell surface. This is evidenced, in part, by the fact that inhibition of carboxylesterase (intracellular) potentiates EA toxicity (Ghanayem et al., 1985b) . Furthermore, the toxicity of acrylates can be altered by the vehicle used for gavage. Butyl acrylate induced acute forestomach toxicity when administered in a waterEmulphor mixture, but not in corn oil. Similarly, the toxicity of EA was greater in water than corn oil. These effects are likely related to the fact that water, but not corn oil, is absorbed by the stomach (Ghanayem et al., 1985b) . Once inside forestomach epithelial cells, EA binding to LMWTs (e.g. GSH) and protein thiols, and potentially enzymatic conversion to acrylic acid begins to induce cellular toxicity. The specific toxic moiety has not yet been identified (Frederick et al., 1992; Sweeney et al., 2004) , but evidence points toward GSH depletion. As indicated above, carboxylesterase inhibition potentiates EA toxicity-indicating that metabolites related to carboxylesterase metabolism (e.g. acrylic acid) are not drivers of toxicity. This is consistent with data indicating that EA is more reactive than acrylic acid (e.g. GSH binding). Similar to the forestomach, studies on the inhalation toxicity of EA suggest that GSH depletion is either the main factor or an important contributor to nasal and olfactory epithelial toxicity (Frederick et al., 2002; Sweeney et al., 2004) . Predictive computation fluid dynamic and physiologically based PBPK models indicated that tissue levels of acrylic acid did not explain the differential toxicity of EA and acrylic acid. When these models were used to estimate reference concentration (RfC) values for EA, the RfC based on acrylic acid tissue levels were much higher than the RfC value based on GSH depletion, and the study authors stated that the latter value was more appropriate (Sweeney et al., 2004 ).
As will be described in Section 3.2, the BMDL 10 values for hyperplasia in male and female rats and mice in the NTP (1986) cancer bioassay ranged from 6 to 22 mg/kg (Table 4 ). The BMDL 50 for GSH depletion in male mice is reported to be 13 mg/kg (Ellis-Hutchings et al., 2017) . Benchmark dose modeling of data in Fig. 4 results in a similar BMDL 50 of 23 mg/kg. A 50% reduction in GSH was considered adverse (i.e. the benchmark response level) based on evidence in Gillette and Frederick (1993) (see below). The similar BMDL values for GSH depletion and hyperplasia indicate that GSH depletion may be causal to the development of cytotoxicity and hyperplasia.
Data indicate that EA is delivered to both the forestomach and glandular stomach. It is unclear, however, if the differences in the forestomach and glandular stomach responses to EA are an issue to delivery of EA to the tissue, pharmacokinetics within the tissue, or pharmacodynamic responses. Considering involvement of GSH, it has been reported that the LMWT levels are 2-4 times higher in the glandular stomach than the forestomach (Potter and Tran, 1993; Udinsky and Frederick, 1994) (Fig. 4) . Furthermore, decrease in GSH in the glandular stomach (Fig. 4B ) are less severe than the forestomach (Fig. 4A) . Notably, within the gastrointestinal tract, the forestomach exhibits the lowest rate of GSH synthesis, whereas the glandular stomach was the highest (Potter and Tran, 1993) . These data may explain the differential toxicity between the forestomach and glandular stomach.
Overall, the reactive binding to LMWT and protein thiols can conceivably be the more toxic element of EA disposition as compared to acrylic acid formation for example. Depletion of GSH can lead to oxidative stress or changes in cell redox status that subsequently alters protein function via protein glutathionylation (Franco and Cidlowski, 2009; Townsend, 2007) . Similarly, binding of EA to protein thiols can conceivably alter their function by preventing normal protein regulation by glutathionylation or nitrosylation status (Franco and Cidlowski, 2009; Townsend, 2007) . Altered thiol status might facilitate or inhibit protein degradation or alter the folding or function of newly synthesized proteins. Any of these events or a combination thereof could facilitate epithelial cell toxicity.
As part of the cytotoxicity response to bolus doses of EA, tissue injury also elicits inflammatory responses. In fact, the principal study reviewer of the NTP (1986) 2-year bioassay noted that the inflammatory responses at 200 mg/kg would have precluded higher dosing. Although a separate key event for inflammation might be warranted, we view the inflammatory response as part of the cytotoxic response. Necrotic cell death, unlike programmed cell death can release pro-inflammatory signals that may acutely help in the response to tissue damage. As discussed in Williams and Iatropoulos (2009) , data indicate that "the carcinogenicity of EA is strictly local, in the forestomach, and does not involve any systemic dispositional considerations. Initially, the effects of EA consist of lysis of the cytoprotective mechanisms that exist on the surface of the forestomach epithelium. This results in probable release of cytokines and the stimulation of acute inflammatory infiltrate, and hyperkeratosis." Counterfactual studies demonstrating Fig. 4 . Dose-and time-dependent depletion of non-protein sulfhydryls in the rat forestomach (A) and glandular stomach (B). Data adapted from Udinsky and Frederick (1994) . C.M. Thompson et al. Regulatory Toxicology and Pharmacology 96 (2018) 178-189 cancer mitigation with anti-inflammatory agents might further inform whether inflammation is a key event separate from cytotoxicity and regenerative hyperplasia.
Key Event 3: chronic regenerative hyperplasia
Chronic cell proliferation is a well-known risk factor for carcinogenesis (Ames et al., 1993; Boobis et al., 2009; Cohen, 2010; Gaylor, 2005) . There is considerable evidence that EA induces regenerative hyperplasia, and the sustained hyperplasia is required for forestomach carcinogenesis. Gavage doses of 100 mg/kg have been shown to induce forestomach toxicity and regenerative hyperplasia with just a few days or weeks (Bernacki et al., 1987b; Frederick et al., 1990; Ghanayem et al., 1985) . Single dose, corn oil gavage of 200 and 400 mg/kg EA to male F344 rats significantly increased forestomach weight 4 h after exposure. Time course analysis after 200 mg/kg EA indicated peak increase in forestomach weight 8 h after exposure, with weight remaining significantly elevated 24 h after exposure (Ghanayem et al., 1985a) . When examined 24 h after a single 200 mg/kg EA gavage, forestomach hyperplasia was not evident (n = 8 rats). However, both two and four consecutive daily gavage doses of 200 mg/kg EA induced forestomach hyperplasia in all rats examined (n = 8 per treatment group). These studies demonstrate that carcinogenic doses of EA induce forestomach hyperplasia as early as two days after commencement of treatment.
Gillette and Frederick conducted 5-bromo-2′-deoxyuridine (Brdu) labelling experiments in rats exposed to 10, 50, or 200 mg/kg EA via gavage for 2 weeks (Gillette and Frederick, 1993) . The authors noted that neither 10 or 50 mg/kg altered the number of S-phase positive cells or structure of the forestomach epithelium, however after 2 weeks of exposure to 200 mg/kg EA, the labelled cells displayed a distinct pattern due to apparent organized folding of the forestomach epithelium. Interestingly, a similar pattern can be seen in labelling experiments after 4 weeks of exposure to the non-genotoxic forestomach carcinogen butylated hydroxyanisole (Cantoreggi et al., 1993) . In contrast, exposure to styrene oxide did not induce tissue folding (Cantoreggi et al., 1993) . It is conceivable that chronic injury to the forestomach epithelial lining causes restructuring and an increase in proliferation and cell population that increases the chance of mutation.
Recovery studies following two weeks of exposure indicate severe effects with 200 mg/kg EA. With no recovery, both 100 mg/kg and 200 mg/kg induced forestomach hyperplasia in 12/12 rats. After 2 weeks of recovery, 0/8 and 8/8 rats exhibited hyperplasia in the 100 mg/kg and 200 mg/kg groups, respectively. After four weeks of recovery, hyperplasia was still evident in all 8 rats that were previously exposed to 200 mg/kg rats (Ghanayem et al., 1986) . Ghanayem et al. (1991b) conducted a reversibility study in F344 rats exposed to 100 and 200 mg/kg EA for 13 weeks via corn oil gavage. Immediately following 13 weeks of exposure, 100% of the exposed rats exhibited forestomach hyperplasia. After 8 weeks of recovery, 1/10 and 6/10 exhibited hyperplasia in the 100 and 200 mg/kg groups, respectively. After 19 months of recovery, hyperplasia was evident in rats in 6, 8, and 31% of the control, 100 mg/kg, and 200 mg/kg rats, respectively (Ghanayem et al., 1991b) . Considering the lack of EA genotoxicity, (see Section 3.4), the hyperplasia evident long after treatment ceased could be the result of increased cell population induced during the treatment phase.
Further, it has been demonstrated that preventing hyperplasia prevents tumor formation. Ghanayem et al. (1993) observed that following 6 months of dosing at the carcinogenic dose of 200 mg/kg EA, followed by 15 months of recovery, neither hyperplasia or forestomach tumors were observed; however, after 12 months of exposure, followed by a 9-month recovery period, forestomach tumors were reported. These data demonstrate that chronic hyperplasia is necessary for tumor formation.
Key Event 4: Expansion of spontaneous mutations
According to U.S. EPA's draft Framework for Determining a Mutagenic Mode of Action (U.S. EPA, 2007), target tissue mutation data provide the strongest evidence for a mutagenic or non-mutagenic MOA. In this regard, a transgenic rodent (TGR) mutation assay for EA failed to detect increase in MF in the stomach following 28 days of exposure up to 50 mg/kg EA (Ellis-Hutchings et al., 2017) , consistent also with lack of DNA damage in the forestomach assessed by comet assay (Morimoto et al., 1990) . Bypassing all oral pharmacokinetic barriers, EA also failed to induce genotoxicity in blood cells when administered by i.p. injection (Ashby et al., 1989; Hara et al., 1994; Kligerman et al., 1991) . As discussed in Section 3.4, in vitro data indicate the EA does not bind DNA and EA is generally negative in multiple in vivo assays (Table 5) . Taken together, the data do not support that EA causes genotoxicity in the forestomach. It is most plausible that spontaneous mutations arise from chronic injury to the forestomach epithelial lining as a result of tissue cytotoxicity and increased proliferation and stem cell population. 
Dose and temporal concordance
Among the Bradford-Hill criteria used for establishing causal relationships, dose-response and temporal concordance are two critical elements. Dose-response concordance demonstrates that intestinal hyperplasia occurs at concentrations that do not induce genotoxicity (Table 5 ). The data for EA indicate a relatively narrow window in which ≥100 mg/kg EA increases cytotoxicity, hyperplasia and carcinogenicity (NTP, 1986) , but ∼20 mg/kg does not increase hyperplasia in 13-week assays (Bernacki et al., 1987b) , and 50 mg/kg does not increase Sphase positive cells after 2 weeks of exposure (Gillette and Frederick, 1993) . Somewhere between 20 mg/kg and 100 mg/kg (or perhaps even between 50 and 100 mg/kg), EA overwhelms detoxification pathways and produces cytotoxicity, regenerative hyperplasia, and cancer. EllisHutchings et al. (2017) showed that the EA depleted LMWTs in the forestomach of transgenic mice. These data were modeled and the 95% lower confidence limit on the benchmark dose (BMDL 50 ) for 50% depletion of GSH was 13.3 mg/kg. Using data in the NTP 2-year cancer bioassay (which employed only three groups: 0, 100, and 200 mg/kg doses), BMD modeling predicts lower BMDL 10 values for hyperplasia than tumor formation for all species and sexes (Table 4 ). The BMDL 10 for hyperplasia ranged from 5 to 31 mg/kg, whereas the BMDL 10 for tumors ranged from 24 to 72 mg/kg. Notwithstanding the vast differences in exposure duration (∼3 h vs 2 yr), the similar BMDL values for GSH depletion and hyperplasia indicate that GSH depletion may be causal in the induction of cytotoxicity and regenerative hyperplasia.
Regarding temporality, 200 mg/kg EA depletes GSH within hours of exposure (Fig. 4) and hyperplasia within one week of exposure (Ghanayem et al., 1985a ). This hyperplasia is unlikely due to cell transformation based on a) the short time frame, b) the lack of EA genotoxicity, and c) the lack of early neoplastic lesions. Instead, the data indicate that rodents receiving high gavage doses of EA experienced a lifetime increase in cell proliferation in the 2-year cancer bioassay in order to regenerate the mucosa. This increase in cell divisions and cell population therefore increases the population of cells at risk for spontaneous mutation during cell division. The carcinogenicity study by Ghanayem et al. (1993) is consistent with these data. Specifically, rats exposed to 200 mg/kg EA for 6 months followed by 15 months without exposure did not exhibit hyperplasia or tumors (Fig. 1) . In contrast, rats exposed to 200 mg/kg EA for 12 followed by 9 months without exposure exhibited forestomach tumors.
Strength, consistency and plausibility
Cytotoxicity and subsequent regenerative hyperplasia is a wellknown MOA for increasing tumor risk (Ames et al., 1993; Boobis et al., 2009; Meek et al., 2003; U.S. EPA, 2005) , and it has been suggested that cytotoxic and proliferative effects observable by 13 weeks of exposure can be predictive of effects in 2-year bioassays (Cohen, 2010; Gaylor, 2005; Slikker et al., 2004) . Indeed, the data for EA demonstrate cytotoxicity almost immediately upon high-dose exposure, and furthermore, stop-dosing studies indicate that prolonged forestomach cytotoxicity and hyperplasia are required to induce forestomach tumors (Ghanayem et al., 1993) . That EA-induced forestomach tumors involves a cytotoxic MOA is not a new concept. For nearly 30 years EA has been discussed as an example of a non-mutagenic, cytotoxicity-driven carcinogen (Butterworth, 1989; Kroes and Wester, 1986 ).
An important element of MOA involves counterfactual research, whereby putative causal key events in the MOA progression can be tested by inducing or blocking a key event experimentally and examining the overall effect on the outcome of interest. Attempts to alter EA toxicity by modulating sulfhydryls are examples of counterfactual studies (Ghanayem et al., 1991a) , although these were confounded (see Section 3.1.2). Differences in carcinogenic outcome between gavage and drinking water dosing has been described as providing counterfactual evidence for a cytotoxic MOA for chloroform (Borgert et al., 2015) . Specifically, higher area under the curve (AUC) blood chloroform levels achieved via drinking water are not carcinogenic to the liver or kidney, whereas cytotoxic bolus concentrations resulting in brief spikes of chloroform levels (but lower AUC) induce hyperplasia and ultimately carcinogenesis. Similarly, drinking water exposure to EA induced forestomach lesions, but at a level insufficient for tumor promotion (see Section 2). The stop-dose studies described in Fig. 1 are a form of counterfactual study, and indicate that prevention of chronic injury to the forestomach epithelial lining and hyperplasia can prevent EA-induced tumor formation (Ghanayem et al., 1993) (Fig. 1). 
Alternative MOAs
Alternative MOAs for EA-induced forestomach cancer might include mitogenic and mutagenic MOAs. With regard to the former, there is no evidence to suggest that EA is mitogenic. For example, S-phase labelling in the forestomach correlates with histopathological lesions in the forestomach (see Sections 3.1.2.2 and 3.1.3). The potential for a mutagenic MOA is discussed in the section below.
Evidence against a mutagenic MOA
All cancers ultimately arise through heritable cellular genetic changes. The critical questions in a risk assessment context is when does mutation take place (i.e., early or late in the sequela of key events). Because both genotoxic and non-genotoxic agents can induce forestomach tumors (Proctor et al., 2007) , one cannot simply assume that EA has a non-genotoxic MOA without formal analysis. The section summarizes the genotoxicity data for EA. In vivo data are presented first, as they most closely inform the MOA within target organs. This is consistent with both the hierarchy that was presented in the draft U.S. EPA guidance (U.S. EPA, 2007) as well as retrospective reviews on MOA determinations (Eastmond, 2012; Thompson et al., 2017a) . Furthermore, this is consistent with the historical development of TGR mutation assays that were designed to investigate mechanisms of cancer findings in rodent cancer bioassays (Lambert et al., 2005) .
Binding of EA and other small acrylate esters to GSH and proteins occurs due to α,β-unsaturated double bond near the carbonyl group in the ester. The β carbon becomes electron deficient and thus susceptible to nucleophilic attack and subsequent alkylation of the nucleophile (Ashby et al., 1989; Friedman et al., 1965; McCarthy et al., 1994) . Because DNA is nucleophilic, there is theoretical potential for EA to bind DNA. However, it has been shown that EA does not bind to naked DNA in vitro (McCarthy et al., 1994) or in the forestomach following gavage (Ghanayem et al., 1987) . Table 5 summarizes non-target and target tissue in vivo genotoxicity results for EA. Among non-target tissues, the in vivo blood micronucleus (MN) assay is commonly used to identify potentially genotoxic agents. No MN studies were identified that used drinking water or dietary exposure scenarios. However, Hara et al. (1994) reported that gavage dosing of up to 750 mg/kg EA did not induce MN (Table 5) . Although studies using intraperitoneal (i.p.) injection do not recapitulate environmental exposures, they can nevertheless provide information on the genotoxic potential of an agent. As shown in Table 5 , four MN assays by the i.p. route are available; by weight of evidence, these show no EA genotoxicity. Ashby et al. (1989) found no bone marrow MN increase in BALB/c and C57Bl/6 mice injected with EA in corn oil (up to 738 mg/kg) and in water (up to 2 × 812 mg/kg, 24 h apart), with multiple sampling times. Similar negative results were observed in BDF1 mice exposed by i.p. injection of up to 750 mg/kg (Hara et al., 1994) . Likewise, Kligerman et al. (1991) found that i.p. injection of C57Bl/6 mice with ≤500 mg/kg EA did not increase chromosomal aberrations or MN in splenocytes. One mouse injected with 1000 mg/kg had significantly elevated MN in splenocytes; the study authors discounted this finding because 1) effects were observed in only one mouse, 2) there was no evidence of an overall dose-response, and 3) there were no corroborating chromosomal aberrations (Kligerman et al., 1991 ). An earlier study described increased MN in bone marrow polychromatic erythrocytes of BALB/c mice given i.p. injection of 225-1800 mg/kg EA in water (Przybojewska et al., 1984) . However, Ashby et al. (1989) could not replicate these positive findings even using identical test conditions and mouse strain. The only other nonoral genotoxicity study demonstrated that dermal exposure of transgenic Tg.AC mice to EA did not increase MN in peripheral blood erythrocytes (Tice et al., 1997) .
Two studies have investigated the genotoxicity of EA in the tissue of carcinogenic concern, i.e. forestomach (Table 5) . A comet assay conducted in male rats exposed to 0.1-4% EA by corn oil gavage (∼25-986 mg/kg) reported no significant damage in the forestomach 3 h after exposure (Morimoto et al., 1990) . More recently, a TGR in vivo mutation assay was conducted in gpt delta mice. Using methods recommended in OECD Test Guideline 488 (OECD, 2013), mice were exposed to ≤50 mg/kg EA in corn oil for 28 days, followed by a 3-day recovery/fixation period (Ellis-Hutchings et al., 2017) . While the positive control benzo(a)pyrene (B[a]P) increased mutant frequencies (MF) in the GPT and SPI assays, EA caused no significant increase in MF. Although the OECD Test Guideline 488 recommends that the top dose in a TGR assay should produce signs of toxicity such that higher dose levels would be expected to produce lethality, the guidance also states that "chemicals which exhibit saturation of toxicokinetic properties may be exceptions to the dose-setting criteria and should be evaluated on a case-by-case basis" (OECD, 2013) . As discussed in Section 3.1.2.2, carcinogenic gavage doses of EA (i.e. ≥100 mg/kg) overwhelm detoxification pathways. Moreover, Ellis-Hutchings et al. (2017) showed that EA depleted LMWTs in the forestomach of transgenic mice at ≥20 mg/kg.
Finally, it should be noted that EA has been examined for dermal carcinogenicity in the transgenic mouse model Tg.AC (see Section 2). This transgenic mouse model is regarded as capable of identifying both genotoxic and non-genotoxic carcinogens (Tennant et al., 1996) . The inability of this animal strain to exhibit positive tumorigenic responses from EA exposure highlights the specificity of EA-induced forestomach tumors, and is consistent with the general lack of in vivo (and in vitro; see below) genotoxicity of EA.
With regard to in vitro genotoxicity testing, four studies evaluating the genotoxicity of multiple chemicals in Ames assay have included results for EA (Emmert et al., 2006; Haworth et al., 1983; Waegemaekers and Bensink, 1984; Zeiger et al., 1992) . Three studies were negative, while one was equivocal (Haworth et al., 1983) . EA was also negative for genotoxicity in Drosophila melanogaster (Valencia et al., 1985) . Studies in mammalian cell lines report positive results in the tk mouse lymphoma assay (Dearfield et al., 1991; Mitchell et al., 1997; Moore et al., 1988 Moore et al., , 1989 , but negative results in Chinese hamster ovary (CHO) cells at the hgprt locus (Moore et al., 1989 (Moore et al., , 1991 . It is clear in some of these studies (Dearfield et al., 1991 ) that genotoxicity correlated with cytotoxicity. Other studies report that positive tk results correlated with dose-dependent decreases in LMWT levels and increases in mitochondrial toxicity (Ciaccio et al., 1998) .
In 2007, a group of experts funded by the European Centre for the Validation of Alternative Methods (ECVAM) developed set of reference compounds to be used to characterize new or improved in vivo and in vitro genotoxicity assays (Kirkland et al., 2008) . The list contained three main subgroups: i) genotoxins that should provide positive results, ii) non-DNA-reactive agents that should provide negative results, and iii) non-DNA-reactive agents that are reported to give tk mutations in the mouse lymphoma assay or other cytogenetic damage (MN or chromosomal aberrations) at high/cytotoxic concentrations-some of which may be carcinogenic and assumed to have non-genotoxic MOA. This latter category of compounds was further characterized as chemicals that should give negative results in in vitro mammalian cell genotoxicity tests despite having some positive reports-especially in mouse lymphoma cells. Notably, EA was included in this group. Subsequent studies from the same authors reported that EA induces positive MN results in cell lines at cytotoxic concentrations or provides only equivocal (e.g. no response trend) results (Fowler et al., 2012; Whitwell et al., 2015) , as well as negative results in Salmonella typhimurium TA102 (Kirkland et al., 2016) . In a recent update to this ECVAM 2008 list of agents, the authors reiterated that the weight of evidence indicates that EA is non-genotoxic and that the rodent forestomach tumors were likely the result of chronic cytotoxicity/irritation (Kirkland et al., 2016 ).
EA has been tested for toxicity within the ToxCast/Tox21 HTS program and was reported to be negative for activity in all assays in which the agent was evaluated. Several assays evaluate p53 activation in human cells, and have been considered indicative of genotoxic potential (IARC, 2017b), although these assays have been questioned for relevancy for genotoxicity (Chiu et al., 2017; IARC, 2017a) .
Overall, the available data indicate that EA is not genotoxic in vivo, and that positive in vitro findings, when observed, are typically observed at cytotoxic concentrations.
Potentially susceptible subpopulations
Based on the proposed MOA, it is theoretically possible that individuals deficient in carboxylesterase activity or glutathione synthesis might be susceptible to EA under unusual prolonged high-dose exposure scenarios. We are not of aware of any research demonstrating such susceptibilities to acrylates, nor are we aware of any diseases related to GSH deficiency or carboxylase deficiencies that have ever been considered in environmental risk assessment. Furthermore, sustained exposure to high concentrations of EA is unlikely due to its low odor threshold of ∼0.5 ppb, disagreeable acrid odor, and its use primarily under strictly controlled industrial hygiene conditions (OECD, 2004) .
Data gaps
As with all datasets, there are some gaps in our knowledge of the detailed sequence of events. However, these gaps represent more of a lack of details in the mechanism of action as opposed to any deficiency in the more general MOA needed for human health risk assessment (U.S. EPA, 2005) . For example, the ability to determine the contribution of LMWT depletion, protein thiol binding, and acrylic acid to the toxicity of EA would enhance detailed understanding of EA toxicity. Earlier attempts to apply PBPK models to identify dose metrics that best correlate with toxicity concluded that depletion of LMWT was a better dose metric than acrylic acid (Frederick et al., 1992; Sweeney et al., 2004) . Additional information on thiol status under repeated exposure scenarios would also be informative.
Molecular research could also further inform the MOA for EA. For example, immunohistochemistry and in situ hybridization techniques could further characterize molecular and histopathological responses to EA. Similarly, toxicogenomic analyses could inform molecular signaling pathways altered by acute and repeated exposure to EA. Although transgenic animals have been used to investigate dermal carcinogenicity and forestomach mutagenicity of EA, there are no published studies using animal models that might further elucidate MOA (e.g. carboxylesterase polymorphisms). Attempts to investigate the role of GSH have all used DEM, which may have pleiotropic effects (i.e., do more than simply deplete GSH). Studies with the glutamate-cysteine ligase inhibitor, L-buthionine-(S,R)-sulfoximine, might shed additional light on the role of GSH in the MOA for EA-induced forestomach cancer.
With regard to the potential for in vivo genotoxicity, information on the specific mutations observed in forestomach tumors relative to spontaneous tumors could be informative. For example, a finding that mutations present in EA-induced tumors are similar to those in spontaneous tumors would provide additional support for promotion or spontaneous mutation being the primary driver. In vivo mutation data at carcinogenic doses might provide additional insight into high dose MOA. Recent examples include (Koenig et al., 2016; Thompson et al., C.M. Thompson et al. Regulatory Toxicology and Pharmacology 96 (2018) 178-189 2015, 2017b). Nevertheless, the frank toxicity induced in the forestomach with higher EA doses would potentially have confounded any significant increases in MF. Finally, the NTP (1986) 2-year cancer bioassay had only two dose groups differing by only 2-fold. The absense of tumors in an additional lower-dose group where EA does not induce hyperplasia (e.g. 20 mg/kg) would further support a threshold MOA.
Human relevance
Human relevance addresses three fundamental questions: 1) is the WOE sufficient to establish the MOA in animals, 2) are the key events plausible in humans, and 3) are the key events plausible in humans after accounting for pharmacokinetics and pharmacodynamics (Boobis et al., 2006; Meek et al., 2003) . With regards to the WOE for the MOA in animals, there is broad consensus that EA induces forestomach tumors through a cytotoxic MOA (Health Canada, 2011; NTP, 2000; NTP, 2004; SCOEL, 2004; Williams and Iatropoulos, 2009) . With regard to whether the MOA is plausible in humans, it should be recognized that a MOA for EA-induced forestomach tumors in rodents may not be relevant to the rodent glandular stomach. In rodents, highly concentrated bolus doses of EA results in delivery of EA to the glandular stomach, increased organ weight/edema, depletion of LMWTs, and even histopathological lesions, yet tumors of the glandular stomach are not observed. These findings suggest that there is organ specificity in rodents for EA-induced cancer. Notably, humans do not possess a forestomach (DeSesso and Jacobson, 2001) , and the rat forestomach pH is less acidic relative to the human gastric stomach and gastric residence time is longer in rats (Williams and Iatropoulos, 2009) . The lack of carcinogenesis in the rodent glandular stomach indicates that the MOA for forestomach tumors in rodents is not relevant to humans. Even if humans possessed a forestomach, consideration of pharmacokinetics and exposure would still support limited human relevance because the major route of human exposure to EA and other small acrylates is via inhalation (IARCSCOEL, 2004) . Proctor et al. (2007) highlighted four important considerations for determining whether a rodent forestomach carcinogen poses a carcinogenic risk to humans. Acknowledging that forestomach cancers can arise from both genotoxic and non-genotoxic agents, Proctor et al. (2007) concluded that forestomach tumors cannot be dismissed as nonrelevant without first weighing the available chemical-specific evidence for genotoxicity, target organ specificity, dosing scenario (e.g., gavage vs. drinking water), and irritation. In the case of EA, the available data indicate that EA 1) is not genotoxic in vivo, 2) only induces forestomach tumors, 3) is only carcinogenic via bolus high concentration gavage dosing, and 4) is only carcinogenic at chronic and repetitive irritating/ damaging doses (Table 6 ). Based on the WOE decision criteria for assessing the relevance of forestomach tumors in human cancer risk assessment described in Proctor et al. (2007) , EA-induced forestomach tumors in rodents would not be considered relevant to humans (Table 6 ).
Conclusion
The WOE strongly supports that EA causes forestomach tumors in rats and mice by a cytotoxicity MOA, which is thresholded, occurring only from chronic high-dose-rate gavage administration at doses equal to or exceeding 100 mg/kg. This finding is consistent with NTP delisting EA as "reasonably anticipated to be carcinogenic to humans" based on low human exposure, specificity of the effect to oral gavage dosing, and evidence of local irritation and cell proliferation of the forestomach (NTP, 2000; NTP, 2004) . Nevertheless, EA remains listed under Proposition 65 as a "chemical known to the State of California" to cause cancer, and IARC currently lists EA as Group 2B, "possibly carcinogenic to humans" (http://monographs.iarc.fr/ENG/Classification/latest_ classif.php) based IARC's evaluation in 1986. After prioritization for review by an IARC advisory body (IARC, 2014) , EA is scheduled for review in 2018 (http://monographs.iarc.fr/ENG/Meetings/index.php). Considering the body of evidence that has been published since 1986 and integrated in the MOA analysis described herein, it is our view that EA does not pose a human cancer hazard or risk.
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